



Australian Government

PCT/AU2004/000466

REC'D 11 MAY 2004

WIPO

PCT

Patent Office
Canberra

I, LEANNE MYNOTT, MANAGER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. 2003901645 for a patent by EIFFEL TECHNOLOGIES LIMITED as filed on 08 April 2003.



WITNESS my hand this
Twenty-eighth day of April 2004

LEANNE MYNOTT
MANAGER EXAMINATION SUPPORT
AND SALES

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

AUSTRALIA

P1001009
Registration 3.2

Patents Act 1990

PROVISIONAL SPECIFICATION

Invention Title: **Particle synthesis apparatus and method**

The invention is described in the following statement:

PARTICLE SYNTHESIS APPARATUS AND METHOD

Field of the Invention

The present invention relates to an apparatus and method for enhancing mass transfer between two substances in different phases which are to be mixed, or one suspended or dissolved in the other. It has particular but not exclusive application to suspending or dissolving particles of a substance, such as a pharmaceutical or biological substance, in a solvent.

Background

Throughout this specification, unless stated otherwise, where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not an admission that the document, act or item of knowledge, or any combination thereof, at the priority date, was part of the common general knowledge.

The invention has many applications but is described herein the context of using dense gases or supercritical fluids to manipulate a substance.

Dense gas techniques utilising fluids, near or above their critical point, as a solvent or anti-solvent have been developed in recent years. At least two dense gas methods have been considered for the production of solid particles, both of which include a step of dissolving the solid in a solvent. The first method is known as the Rapid Expansion of Supercritical Solutions (RESS), and involves expanding a supercritical solution of the material of interest through a nozzle. Whilst providing an effective method for producing particles in some circumstances, the applicability of the RESS method is limited by the low solubility of proteins and other pharmaceuticals in dense gasses. To overcome this, a high solvent:solute ratio required, which increases costs in both purchasing and handling the high volumes of solvent required. Even so, processing times are long given mass transfer limitations of the process as the particles are formed. In effect, these processing times impose a limit on the maximum flow rate of the dense gas.

The second method, known as the gas anti-solvent (GAS) process, involves

rapidly precipitating solutes from organic solutions, typically using an anti-solvent, such as dense carbon dioxide. The anti-solvent expands the solution, thereby decreasing the solvation power of the solvent, and eventually resulting in the precipitation of the solute. Gas anti-solvent processes have been utilised for the generation of micron-sized particles in two modes. The first mode, known simply as the gas anti-solvent process (GAS), involves the gradual addition of an anti-solvent to the organic solution containing the solute until the precipitation occurs. The second mode, known as the Aerosol Solvent Extraction System (ASES), involves continuous introduction of a solution containing the solute of interest through a nozzle into a flowing dense gas stream. As the solution is sprayed in to the dense gas, high degrees of supersaturation result in the precipitation of fine particles. However, again, these processes are inefficient as they provide limited contact between the solute and the dense gas, which limits the efficiency of the process.

- One example of a known apparatus for the RESS process is set out in Figure 1. As can be seen, solvent (such as CO₂) enters a pump B at A and flows through a valve C where its path divides, which is controlled by valves D and E. CO₂ proceeding to the equilibrium cell F via heating coil G enters the cell in which the solute has already been located. The solute dissolves in the equilibrium cell F. This step is usually rate-limiting for the whole process. Filter H prevents undissolved solute from passing further through the system. Equilibrium cell F is located within water bath J which is maintained at a constant temperature by heater K. The CO₂/solute "solution" then passes from filter H at a temperature and pressure monitored by the temperature indicator T1 and pressure indicator PI and through valve D to heated region L into an expansion chamber M where precipitation of the solute occurs. This may be assisted by direct solvent passing from valve C through heating coil N and valve E. Particles can be retrieved from expansion chamber M and some are trapped by filter P where they are carried by the exhaust of the solvent.
- This invention is directed towards an apparatus which operates in a more efficient manner and enables greater and quicker solution dissolution of solute in the solvent, which is often a rate-limiting step as outlined above.

Summary of the invention

The invention therefore provides an apparatus for dissolving or suspending a substance in a solvent, the apparatus comprising:

- 5 • an outer chamber having an inlet for fluid and an outlet for fluid and adapted to contain a dense gas or supercritical fluid;
- a porous chamber located within the outer chamber adapted to contain the substance; and
- means to create turbulence within the porous chamber.

10 It has been found that this apparatus, used in place of equilibrium chamber F in Figure 1 (and which does not require water bath J either) enables faster and better dissolution of solute in the super critical fluid (eg. CO₂).

15 In a preferred form of the invention the porous chamber is manufactured from a sintered material, preferably stainless steel. The porous chamber may be cylindrical in shape, with the base and sides being porous. The pores in the wall(s) and base of the porous chamber are preferably created by sintering. The pores may be about 0.5 to 5 microns diameter, preferably about 1 micron. The outer chamber may conveniently be an autoclave.

20 In one example, the porous chamber is cylindrical in shape, with a diameter of about 50 mm and height of 100 mm in an outer chamber of 1 litre capacity. The inlet in the outer chamber may deliver fluid directly to a mouth within the porous inner chamber. Alternatively, the mouth of the inlet is in the wall of the outer chamber, outside the porous chamber. In another embodiment, there are inlets in both these positions.

25 The outlet is desirably located outside the porous chamber. The outlet may be a tube having a mouth in the outer chamber, outside the porous chamber, and leading outside the outer chamber. The tube may lead to an expansion chamber for a RESS particle precipitation for example. Alternatively, the outlet may be

directly connected to a nozzle for solution expansion.

The means for creating turbulence may include a stirrer located within the chamber and driving means to drive the stirrer, or rotation of the chamber itself.

The driving means may be a magnetic stirrer driver which is preferably
5 capable of rotating the stirrer at speeds of 500 to 4000 rpm while the chamber is pressurised with dense gas. About 800 rpm is one useful speed of rotation.

In another form, the driving means is a magnetic driver which rotates the porous inner chamber about an axis. To effect sufficient turbulence within the chamber, the rotation speed of the inner chamber is preferably 200 rpm to
10 3000 rpm and more preferably 500-1500 rpm, and most preferably around 800 rpm.

To further increase turbulence, the outer chamber may further include baffles on its interior surface. These baffles extend from the interior surface of the outer chamber and may extend to be in the proximity of the inner chamber. The
15 baffles increase turbulence within the outer chamber during operation and it is believed that this turbulence reduces the tendency of the solvent to move towards the walls of the outer chamber.

The substance may be in a solid phase and it may be in particulate form. Preferably, the resulting solution is used in a dense gas or supercritical fluid
20 process. The porous chamber may be provided with a plug to hold the solute against the base of the chamber. The plug may be a planar element (of the same cross-sectional shape as the chamber) abutting the sides of the porous chamber held against the solute by a resilient biasing means, such as a spring.

In use, the solvent is fed continuously into the outer chamber, creating a
25 higher pressure which urges the solvent into contact with the solute in the inner chamber. The resulting solution then passes through or is drawn through the outlet. Hence the solute is transferred in solution from the porous chamber where it is extracted from the outer chamber.

A preferred use of the invention is the formation of fine particles of the substance from a substance/dense gas solution. This applies to the GAS process, or its variations, and also the RESS process described above. This alleviates a significant problem in scaling-up and making these processes continuous. In the
5 RESS process, the solution passing from the porous chamber through the pores into the outer chamber may be permitted to flow out of the outer chamber under its own pressure through a valve at the outlet at a controlled rate such that it expands, thus precipitating fine particles of the substance.

In one preferred use of the invention, the substance is located in the porous
10 stainless steel chamber and the outer chamber is then pressurised by dense fluid being introduced into the environment around the inner chamber, defined by the outer chamber. The flow rate of the dense fluid can be adjusted to optimise particle dissolution. In some cases, it may be desirable to have a mixture of dense gases or a modified dense gas (ie, a mixture of dense gas and modifier). The
15 stirrer or rotating porous chamber creates rapid movement of particles of the substance and fluids within the porous chamber. It also induces convection within the porous chamber and effectively increases the available surface area of the solute. In this turbulent environment, the solid phase substance dissolves in the dense gas, and then flows out as the dense gas/solute "solution" from the porous
20 chamber through the sintered pores, and then through the outlet.

In another preferred form of the invention, the dense fluid is introduced through an axial shaft directly into the porous chamber. Thus with the rotation of the porous chamber, there is a forced convection flow of dense fluid, which may be CO₂, into the chamber and through the porous walls of the chamber. As the
25 dense fluid is delivered to the porous chamber under critical or near critical conditions, it contacts and forms a solution with the solute. The convective flow of the dense fluid/solute "solution" through the chamber walls is then passed to the outlet of the outer chamber.

In a preferred form of the invention, the porous chamber is provided
30 with a longitudinally extending shaft which defines an annular region in the porous chamber. The solute is positioned within the annular region and dense fluid fed

into the longitudinally extending shaft. The shaft is porous or perforated to allow contact of the dense fluid and solute over the length of shaft in contact with solute. This arrangement further increases the available contact surface area for the dense fluid to diffuse into solute bed. This arrangement has the benefit of
5 providing forced convective flow of dense fluid through the porous wall and increased passage of gas through the packed solute in the annular region.

Without being bound by any particular theory or mode of action, it is believed that the hydrodynamics within a chamber of known apparatus are a constraint on particle generation. In the apparatus of the invention, the rotating
10 chamber or stirrer increases turbulence within the chamber which, in turn, decreases the size of the boundary layer between particles of the substance (solute) and the dense gas flowing around it, within which mass transfer is severely limited. This aids in increasing the efficiency of contact between solute and solvent. This therefore enables a significant increase in the limits of the
15 maximum flow rate of the solute/dense gas solution in a process otherwise limited by the slowness with which the solute dissolves in the dense gas. Accordingly, in one use, particle precipitation processes are quicker and more efficient than known processes with use of the invention because dissolution of the substance (solute) is quicker.

20 Increased speed of production through reduced residence time is an important advantage achieved, as a result of the improved contact between the dense gas and solute. Further, the apparatus also provides better mass transfer. There is also a reduction in time required to achieve saturation of solute in the dense gas. The apparatus has the ability of being scaled up to a larger capacity,
25 to run continuously and for longer run times to make it more attractive for industrial applicability.

One means of making the process at least semi-continuous is to run more than one apparatus in parallel operation so that multiple batches are being processed simultaneously.

30 The invention also provides a method for producing fine particles using

apparatus according to the invention. The invention also provides fine particles produced according to the apparatus of the invention. Preferably the substance is a biologically active substance. More preferably, the substance is a pharmaceutical or biological active used for diagnostic or therapeutic purposes.

5. In another aspect, the dense fluid comprises a modifying agent to modify the polarity of the dense gas. The method of the present invention is capable of producing fine particles of the substance, and is particularly useful for the production of fine particles of pH sensitive substances and biologically active substances, since the biological activity of such substances may be retained.

10 The modifying agent may be present in an amount sufficient to modify the dense gas as required for the end use of the dense gas process.

The dense gas can be at various temperatures and pressures. Preferably the temperature of the dense gas is in the range of -20°C to about 100°C, most preferably about 5°C to about 45°C. The lower temperatures result in increased
15 viscosity and reduced mass transfer properties, and this reduces the efficiency of the method. High temperatures are more costly to run and may damage the substance. Preferably the dense gas has a pressure in the range of about 1 bar to 400 bar. A pressure between about 5 to 200 bar is particularly preferred.

The particles produced by the method of the invention may also include
20 delivery agents such as liposomes, lipids (including phospholipids), water soluble polymers, controlled-delivery coatings, surfactants, phytosterols, and any other delivery agents known in the art.

Preferably, at least half, and more preferably substantially all, of the fine particles produced by the method of the invention have a particle size less than
25 10,000 nm. More preferably, the fine particles have a size no greater than 6,500 nm. Particles having a size in the range of up to 5,000 nm are particularly useful for administration to the lung. If smaller particles are desired, it is believed that the method of the present invention can produce particles down to nanometre size.

The active substance is preferably selected from the group consisting of an antimicrobial agent, virus, antiviral agent, antifungal pharmaceutical, antibiotic, nucleotide, DNA, antisense DNA, RNA, antisense RNA, amino acid, peptide, protein, enzyme, hormones, immune suppressant, protease inhibitors, 5 thrombolytic anticoagulant, central nervous system stimulant, decongestant, diuretic vasodilator, antipsychotic, neurotransmitter, sedative, anaesthetic, surfactant, analgesic, anticancer agent, anti-inflammatory, antioxidant, antihistamine, vitamin, mineral, sterol, phytosterol, lipid and esters of fatty acids.

The active substance may also be selected from proteins, polypeptides, 10 peptides, peptide analogs or peptide mimetics. Most preferably, the pH-sensitive, biologically active substance is selected from the proteins insulin, erythropoietin, calcitonin, LHRH, somatostatin, epidermal growth factors, DNase, platelet derived growth factors, interleukins, interferons, cytokines, peptides of immunoglobulins, TNF and other biologically active peptides, monoclonal antibodies based on TNF 15 inhibitors as well as antibodies based on inhibitors of cytokines and interleukins.

In a second aspect, the present invention provides a pharmaceutical composition comprising particles of the active substance produced by the method of the present invention.

The pharmaceutical composition is preferably in a form suitable for 20 inhalation delivery, for example, for delivery by a metered dose inhaler or a nebuliser. Further, a transdermal delivery system may be used (eg, recent devices involving laser-generated or high-pressure dermal channels) and more traditional parenteral administration.

In a third aspect, the present invention provides a method of treatment of a 25 subject, the method comprising administering to the subject, an effective amount of particles of a biologically active substance produced by the method or apparatus of the present invention.

Further, the use of such an apparatus allows higher yield and recovery of particles per run, the ability to process more material per run with longer run times,

all of which lead to a more efficient process and greater production capacity.

Such an apparatus can be readily scaled up to process larger amounts of material.

5 The performance of the apparatus may be further enhanced by vibration and/or sonication/ultrasonication of the precipitation chamber. Again, without being limited to a mode of action, it is believed that this increases turbulence which increases efficacy. Other means of increasing turbulence may therefore be provided.

10 In the description, the term "dense gas" means a fluid near or above its critical pressure (P_c) and temperature (T_c). In practice, the pressure of the fluid is likely to be in the range $(0.5 - 1.5)P_c$ and its temperature $(0.5 - 1.2)T_c$. The terms "dense fluid" and "expanded fluid" are used synonymously.

15 It will be understood that the term "comprises" (or its grammatical variants) as used in this specification is equivalent to the term "includes" and should not be taken as excluding the presence of other elements or features.

The method of the present invention, in its preferred forms, may provide one or more of the following advantages:

1. increased and quicker solubility of a desired solute in a solvent, especially for use downstream in another process;
- 20 2. drug particle formation in the absence of organic solvents which can be expensive to handle and fully extract;
3. increased efficiency of dense gas and supercritical fluid processes through greater and quicker generation of solutions, particularly solutions closer to saturation.

25 **Brief Description of Drawings**

In order that the invention may be more readily understood, we provide the following non-limiting embodiments as examples.

Figure 1 is a schematic diagram of a prior art process;

Figure 2 is a schematic diagram of an embodiment of an apparatus that may be used in the process of the present invention;

Figure 3 is a schematic diagram of an enlarged part of the apparatus shown
5 in Figure 2;

Figures 4 (a) to (c) are schematic diagrams of alternative dense fluid and solution transfer paths in accordance with the invention; and

Figures 5 (a) to (e) is a series of diagrams illustrating the progressive contact of solute and dense fluid in the apparatus of the present invention.

10 In this embodiment of the invention shown in Figure 2, there is provided an autoclave or outer chamber 1 in which a porous inner chamber 2, the walls of which are preferably made from sintered metal such as stainless steel, is located. A means to create turbulence is provided. In the embodiment of Figure 2, the turbulence is provided by the chamber being mounted on a rotatable mount
15 which can be rotated at speeds of 200 to 3000 rpm. In an alternative embodiment the turbulence may be a stirring mechanism which may be magnetic, with a drive assembly located outside autoclave 1, and the stirrer itself located within porous chamber 2.

There is also provided (but not shown) an inlet for solvent into autoclave 1.
20 Solvent such as CO₂ may be introduced through this inlet to space 7. The solute is pre-loaded into porous chamber 2 within autoclave 1 before the commencement of the dissolution process.

In Figure 3, an internal side view of chamber 2 is shown. This shows the porous metal wall 4 of the chamber 2 with pore sizes of, for example, 1 to 5
25 microns. A resilient biasing means, namely spring 6, is located above a Teflon® plug 5 so as to maintain the as yet undissolved solute in a compact formation.

In use, solute is loaded into chamber 2. The chamber is then agitated to

increase turbulence, primarily by rotation, either of the whole chamber itself, or a stirrer assembly within the chamber driven magnetically by an external drive assembly. This creates turbulence within chamber 2. Turbulence may also be created, or may be increased, by sonication or agitation of the entire apparatus.

5 Additionally, the inner surface of the outer chamber 1 may be provided with baffles 8 which it is believed to increase turbulence and reduces circulating currents of solvent forming close to the inner surface of the outer chamber and thereby improve mass transfer of the solvent to the walls of the inner chamber. These baffles 8 shown as 5mm perpendicular plates preferably extend from the
10 outer chamber across the gap and may even extend to close proximity to the inner chamber. There may be any number of baffles with 2 shown in Figure 2. These baffles are preferably spaced evenly around the inner wall of the outer chamber 1.

 In the embodiment shown in Figure 4(a) through an inlet (not shown) in the side or top wall 11, solvent is added to the autoclave 1 such that it reaches near
15 critical or supercritical temperature and pressure in the chamber. The dense gas solvent permeates through the walls of the porous chamber where it contacts and dissolves some solute and then the resulting solution diffuses out into the autoclave space 7 surrounding the chamber. Hence, a bi-directional flow of both
20 solute and dense fluid is established. The solution is then passed through an outlet for precipitation.

 In Figure 5, the flow of dense fluid into the porous chamber and out of the outer chamber is shown. In Figure 5 (a), the porous chamber is full and progressively empties (Figures 5 (b) to (d) until it is empty (Figure 5 (e)).

 In the embodiment shown in Figure 4 (b), the dense fluid is introduced
25 through an axial shaft 10 directly into the porous chamber 2. With the rotation of the porous chamber 2, there is a forced convection flow of dense fluid, into the chamber 2 and through the porous walls of the chamber. As the dense fluid is delivered to the porous chamber under critical or near critical conditions, it contacts and forms a solution with the solute. The convective flow of the dense
30 fluid/solute solution through the chamber walls to outer chamber space 7 is then

passed to the outlet of the outer chamber.

In an embodiment of the invention shown in Figure 4 (c), the porous chamber 2 is provided with a longitudinally extending shaft 12 which defines an annular region 13 in the porous chamber 2. The solute is positioned within the annular region 13 and dense fluid fed into the longitudinally extending shaft 12. The shaft 12 is porous or perforated to allow contact of the dense fluid and solute over the length of shaft in contact with solute. This arrangement further increases the available contact surface area for the dense fluid to diffuse into solute bed. This arrangement has the benefit of providing forced convective flow of dense fluid through the porous wall and increased passage of gas through the packed solute in the annular region.

The depressurisation after this point may occur through an exit nozzle 8 to facilitate precipitation of the solute out of solution into fine particles which may then be recovered. Alternatively, the solution may be kept at temperature and/or pressure well above atmospheric for further processing downstream of this dissolution apparatus.

While suitable for any of the proteins mentioned above, the examples illustrating the invention are described using ibuprofen and simvastatin as the desired active ingredient. Similarly, for the purposes of illustration, the examples describe the use of CO₂ as the anti-solvent. These compounds represent a highly CO₂ soluble and poorly CO₂ soluble compound respectively.

Example 1

A quantity of ibuprofen was added to the inner porous chamber of the apparatus shown in Figure 2 and the plug put in place. CO₂ was then introduced continuously into the outer chamber. Table 1 shows the process conditions for the Example and results of the Example.

Table 1 – Ibuprofen HiG RESS Processing Results

Compound	Ibuprofen
MW, g/mol	206.3
Equilibrium solubility in CO ₂ , mole fraction	3.20E-03
Temperature, °C	38.5
Pressure, bar	150
Stirring Speed, rpm	800
CO ₂ Flowrate, ml/min	50 ± 20
Total Volume of CO ₂ , L	6
Mass of Product Initially, g	7.5
Mass of product collected, g	4.35
Recover, %	58
Processing Efficiency, g product/L CO ₂	1.25
Dynamic Solubility, HiG RESS	3.14E-04
Nozzle Diameter, mm	2

The dynamic solubility is considerably lower than the equilibrium solution. This is because the equilibrium solubility is obtained at ideal conditions. The dynamic solubility for the small scale (or conventional) processing are unavailable.

- 5 The volume of CO₂ passed through the HiG RESS trials was more than required to process the ibuprofen, hence the efficiency is lower. Overall recovery is low since a lot of product was lost through the 0.5 micron filter. This indicates that a considerable amount of product had a particle size of <0.5 µm.

Example 2

- 10 A similar Example was run for simvastatin. Simvastatin is a solid pharmaceutical at normal temperature and pressure, which is used therapeutically as an HMG-CoA reductase inhibitor. It is readily available commercially. Liquid carbon dioxide (Industrial Grade 99.95%) is available from BOC Gases.

- 15 The simvastatin is heated in the chamber and held with minimal gap between the top of the powder and the Teflon® plug by the spring. CO₂ is added to the autoclave surrounding the chamber as a dense gas and the chamber spun at 800 rpm.

Fresh dense gas is added and gas from the autoclave is extracted by its own pressure through an escape nozzle. This gas has dissolved simvastatin in it for further processing.

Example 2

5 **Table 2**

Compound	Simvastatin
MW, g/mol	418.2
Equilibrium solubility in CO ₂ , dynamic small scale, mole fraction	6.60E-05
Temperature, °C	46.2
Pressure, bar	160
Stirring Speed, rpm	800
CO ₂ Flowrate, ml/min	40 ± 5
Total Volume of CO ₂ , L	25.87
Mass of Product initially, g	5.51
Mass of product collected, g	4.86
Recover, %	88
Processing Efficiency, g product/L CO ₂	0.21
HIG RESS Processing solubility, mole fraction	2.64E-05
Efficiency Improvement over conventional, %	299
Nozzle Diameter, mm	2

The efficiency gain is compared to a dynamic rig using a packed bed versus the HIG RESS rotating cylinder technique and is thus more representative of the potential efficiency gain for dynamic processing.

10

It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the

individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.

Eiffel Technologies Limited
By its Registered Patent Attorneys
5 Freehills Carter Smith Beadle

8 April 2003




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**